{"id":"NCT00506389","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707)","officialTitle":"A Six-Week Double-Blind Randomized, Placebo-Controlled, Parallel Group, Efficacy and Safety, Sleep Lab Trial With Org 50081 in Patients With Chronic Primary Insomnia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-06-06","primaryCompletion":"2008-02-13","completion":"2008-02-13","firstPosted":"2007-07-25","resultsPosted":"2014-08-06","lastUpdate":"2018-10-02"},"enrollment":419,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Insomnia"],"interventions":[{"type":"DRUG","name":"Esmirtazapine","otherNames":["ORG 50081"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Esmirtazapine 3.0 mg","type":"EXPERIMENTAL"},{"label":"Esmirtazapine 4.5 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this trial is to investigate the efficacy, safety and tolerability of esmirtazapine (Org 50081) compared to placebo in patients with chronic primary insomnia.","primaryOutcome":{"measure":"Average Wake Time After Sleep Onset (WASO) During the In-Treatment Period","timeFrame":"From Day 1 to Day 36","effectByArm":[{"arm":"Esmirtazapine 3.0 mg","deltaMin":45.6,"sd":25.7},{"arm":"Esmirtazapine 4.5 mg","deltaMin":45.5,"sd":26.5},{"arm":"Placebo","deltaMin":76.1,"sd":46}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":9},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["26047892"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":139},"commonTop":["Somnolence","Headache"]}}